Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=848 Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
Chemotherapy-Induced Nausea and Vomiting
Primary: Number of Patients Who Reported No Vomiting — 324; 252 Participants — p=<0.01
Phase 2 N=136 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Nausea · Vomiting · Glioma
Primary: Proportion of Patients Achieving Complete Control (CC) — 0.59; 0.55 proportion of patients
Phase 4 N=414 Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)
Chemotherapy-induced Nausea and Vomiting
Primary: The Probability of Complete Responses Over Three Cycles of Chemotherapy After the Start of the MEC Administration — 0.810; 0.718 Probability of complete response — p=<0.05
Phase 2 N=22 Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Nausea With Vomiting Chemotherapy-Induced
Primary: Complete Acute Response — 4; 4; 3 Participants
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 2 N=100 Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)
Chemotherapy-induced Nausea and Vomiting
Primary: Acute and Delayed Chemotherapy-Induced Nausea. The Self-reported Instruments Are Documented After the Chemotherapy Sessions and Collected on Study Visits 1, 2, and 3…
Phase 3 N=69 Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Germ Cell Tumors
Primary: Complete Response. — 47; 15 percentage of evaluable subjects
Phase 2 N=85 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
Chemotherapy-Induced Nausea and Vomiting · Ovarian Cancer
Primary: Efficacy of the Aprepitant/Ramosetron/Dexamethasone Regimen in Terms of the Proportion of Patients With a Complete Response (CR) During the 120 Hour Following Initiation…
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Phase 3 N=710 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Nausea and Vomiting, Chemotherapy-Induced
Primary: Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately…
Phase 2 N=54 Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
Colorectal Cancer · Nausea and Vomiting
Primary: Number of Participants With no Emesis and no Rescue Therapy Within 5 Days of Receiving FOLFOX and FOLFIRI in the First Cycle of Chemotherapy. — 54 Participants
Phase 3 N=120 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced Nausea and Vomiting
Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397
Phase 3 N=1,015 Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC) — 78.9; 68.5 Percentage of…
Phase 2 N=68 Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage
Phase 2 N=150 Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
Phase 3 N=555 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 70.1; 61.9 percentage of participants — p=0.043
Phase 3 N=532 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 72.7; 58.4 percentage of participants — p=<0.001
Phase 3 N=1,369 Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 71.3; 61.6 percentage of particpants — p=<0.001
Phase 3 N=307 A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
Chemotherapy Induced Nausea and Vomiting
Primary: Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1 — 50.7; 26.0 Percentage of participants — p=<0.01
Phase 3 N=502 Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
Chemotherapy-Induced Nausea and Vomiting
Primary: Proportion of Patients With Complete Response 0 to 24 Hours (Acute Phase) in Cycle 1 — 54.2; 59.4; 58.6 percentage of patients
Phase 3 N=421 Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1 — 0.696; 0.570…
Phase 2 N=36 A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Primary: Percentage of Participants With Complete Response (CR) During Acute Period (0 to 24 Hours) After Receiving Treatment on Day 1 — 88.2 percentage of participants
Phase 3 N=402 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Chemotherapy-induced Nausea and Vomiting
Primary: Number of Participants With Treatment-emergent AEs at Cycle 1 — 121; 122 Participants
Phase 3 N=942 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Chemotherapy-induced Nausea and Vomiting
Primary: Delayed Phase Complete Response (CR) Rate — 64.7; 56.6 percentage of participants
Phase 2 N=65 Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting — 29.6; 46.3; 24.1 percentage of participants
Phase 2 N=189 Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Radiotherapy-induced Nausea and Vomiting (RINV)
Primary: Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third…
Phase 3 N=2,322 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin). — 795; 820 Participants
Phase 4 N=103 Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Chemotherapy-induced Nausea and Vomiting
Primary: Percentage of Participants in Cycle 1 Who Experienced One or More Adverse Events (AEs) — 80.0 Percentage of Participants
Phase 3 N=380 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants